300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Email
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Retail
Oil and Gas
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Medical Device
B2B
Social Network
Sports
Legal
Wellness
Automotive
eSports
Biotechnology
Education
Renewable Energy
Facebook
Blockchain
Software
Theatre
Beauty
Fashion
Medical
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Web3
Recruiting
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Singapore
Oman
Burkina Faso
Africa
LATAM
Puerto Rico
Poland
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
New Zealand
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Paraguay
Seychelles
Botswana
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Lorence Kim, Co-founder and Managing Partner at Ascenta Capital

Lorence Kim

Co-founder and Managing Partner @ Ascenta Capital

Cambridge, United States

Lorence Kim is a Series C investor at Ascenta Capital in Cambridge focused on Biotechnology and Health Care. Lorence Kim is based out of New York, New York, and is the Co-founder and Managing Partner of Ascenta Capital and the Board of Director of Triana Biomedicines. Lorence previously worked at Flare Therapeutics as a Board Member. Lorence Kim attended the Harvard University.

Total investments:
5
Last investment:
Lead investor:
60%

Last updated:

Industries Lorence Kim invests in

BiotechnologyHealth CareTherapeuticsPharmaceuticalMedical

Stages Lorence Kim invests in

Series CSeries B

Countries Lorence Kim invests in

United StatesGermany

Contacts

TypeContactValidation
Work email
Personal email
Work phone
Personal phone
Socials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Biotechnology 4 (80%)
  • Health Care 3 (60%)
  • Therapeutics 2 (40%)
  • Pharmaceutical 2 (40%)
  • Medical 1 (20%)
See all 7 industries →

Stage

  • Series C 3 (60%)
  • Series B 2 (40%)

Country

  • United States 3 (60%)
  • Germany 1 (20%)

Investments

CompanyDescriptionRoundLinks
Triana Biomedicines Triana Biomedicines
Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas. $120M / Series B / Dec 03, 2025
Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. $400.6M / Series C / Oct 15, 2025
Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. $101M / Series C / Dec 05, 2023
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired andfunctional protein is restored. It was founded in 2019 and is headquartered in San Diego, California. $200M / Series C / Aug 09, 2023
ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired andfunctional protein is restored. It was founded in 2019 and is headquartered in San Diego, California. $46M / Series B / Jan 20, 2023

Co-Investors

Ascenta Capital

About Ascenta Capital

VC Fund · New York, United States

Ascenta Capital is a private equity and venture capital firm.

Ascenta Capital Contacts

NameEmailPhoneSocials
Lorence Kim
Lorence Kim Co-founder and Managing Partner

Sign up to unlock verified contacts

Unlock Contacts

See all 1 contact →

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Email
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Retail
Oil and Gas
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Medical Device
B2B
Social Network
Sports
Legal
Wellness
Automotive
eSports
Biotechnology
Education
Renewable Energy
Facebook
Blockchain
Software
Theatre
Beauty
Fashion
Medical
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Web3
Recruiting
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Singapore
Oman
Burkina Faso
Africa
LATAM
Puerto Rico
Poland
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
New Zealand
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Paraguay
Seychelles
Botswana
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Lorence Kim invest in?

Lorence Kim invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series C and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Lorence Kim?

Public channels for Lorence Kim include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

When did Lorence Kim last invest?

The most recent investment recorded for Lorence Kim closed in Dec 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Lorence Kim Lorence Kim Find email